Patent details

Basic Information

Publication number:

EP2279007

PCT Application Number:

PCT/EP/2009/055194

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP097381818

PCT Publication Number:

WO/2009/133137

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS

French Title of Invention:

HORMONE DE CROISSANCE HUMAINE RECOMBINANTE PEGYLÉE

German Title of Invention:

PEGYLIERTE REKOMBINANTE HUMANE WACHSTUMSHORMON-VERBINDUNGEN

SPC Number:

Dates

Filing date:

29/04/2009

Grant date:

18/05/2016

EP Publication Date:

18/05/2016

PCT Publication Date:

05/11/2009

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

02/02/2011

EP B1 Publication Date:

18/05/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

29/04/2029

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

26/07/2017

 

 

Name:

Ascendis Pharma Endocrinology Division A/S

Address:

Tuborg Boulevard 5, 2900, Hellerup, Denmark (DK)

History of Owners

From:

29/04/2009

To:

26/07/2017

Name:

Ascendis Pharma Growth Disorders Division A/S

Address:

Tuborg Boulevard 12, 2900 Hellerup, Denmark (DK)

Agent

Name:

Office FREYLINGER S.A.

From:

02/08/2017

Address:

PO Box 48, 8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

LESSMANN Torben

Address:

Germany (DE)

2

Name:

KINDERMANN Susanne

Address:

Switzerland (CH)

3

Name:

RASMUSSEN Grethe Nørskov

Address:

Denmark (DK)

4

Name:

RAU Harald

Address:

Germany (DE)

5

Name:

SPROGØE Kennett

Address:

United States (US)

6

Name:

HERSEL Ulrich

Address:

Germany (DE)

7

Name:

WEGGE Thomas

Address:

Germany (DE)

Priority

1

Priority Number:

08155408

Priority Date:

29/04/2008

Priority Country:

European Patent Office (EPO) (EP)

2

Priority Number:

08162865

Priority Date:

22/08/2008

Priority Country:

European Patent Office (EPO) (EP)

3

Priority Number:

08167289

Priority Date:

22/10/2008

Priority Country:

European Patent Office (EPO) (EP)

Classification

Main IPC Class:

A61K 47/48;

Publication

Bulletin

Bulletin Heading:

CO

Bulletin edition number:

2017/04

Publication date:

04/08/2017

Description:

Section M : Transfers of property (Art. 53 of the law), change of name and/or address

Deed

Change of owner(s)

Change Kind/ Decision Type:

Change of owner(s) name/address

Deed Number:

RC20170000264A

Date Registered:

26/07/2017

Licence Effective Date:

Licence Expiration Date:

Scope of Licence:

Deed Filer:

OFFICE FREYLINGER S.A.

Journal Edition Number:

Text:

Country Code:

Updated Licence Number:

Terminated Licence Number:

Added Owner(s)

Name:

Ascendis Pharma Endocrinology Division A/S

Address:

Tuborg Boulevard 5, 2900, Hellerup, Denmark (DK)

Removed Pledgee

Name:

Address:

Annual Fees

Annual Fee Due Date:

30/04/2026

Annual Fee Number:

18

Annual Fee Amount:

262 Euro

Expected Payer:

Last Annual Fee Payment Date:

17/04/2025

Last Annual Fee Paid Number:

17

Last Annual Fee Paid Amount:

246 Euro

Payer:

PAVIS PAYMENTS GMBH

Filing date	Document type	Number of pages
16/08/2017	Outgoing Correspondence	1
26/07/2017	Request For Change	1
02/08/2017	Power Of Attorney	1